Synta Pharmaceuticals to Present at the Jefferies Global Life Sciences Conference

Company to Webcast Presentation on June 10
LEXINGTON, Mass.–(Business Wire)–
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused
on discovering, developing, and commercializing small molecule drugs to treat
severe medical conditions, today announced that the Company will be presenting
at the Jefferies Global Life Sciences Conference on Thursday, June 10 at 3:30
p.m. (ET) in New York.

A live audio webcast and replay of the presentation will be available on the
“Investors” section of the Company’s website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend and
enhance the lives of patients with severe medical conditions, including cancer
and chronic inflammatory diseases. Synta has a unique chemical compound library,
an integrated discovery engine, and a diverse pipeline of clinical- and
preclinical-stage drug candidates with distinct mechanisms of action and novel
chemical structures. All Synta drug candidates were invented by Synta scientists
using our compound library and discovery capabilities. For more information,
please visit www.syntapharma.com.

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125

Copyright Business Wire 2010

Scientists unravel chemistry of Titan’s hazy atmosphere

Washington, September 16 (ANI): In a new research, a team of scientists has unraveled the chemical evolution of the orange-brownish colored atmosphere of Saturn’s moon Titan, the only solar system body besides Venus and Earth with a solid surface and thick atmosphere.

Scientists at University of Hawai’i at Manoa carried out the research.

The UH Manoa team, including Xibin Gu and Seol Kim, conducted simulation experiments mimicking the chemical reactions in Titan’s atmosphere utilizing crossed molecular beams in which the consequence of a single collision between molecules can be followed.

The team’s experiments indicate that triacetylene can be formed by a single collision of a “radical” ethynyl molecule and a diacetylene molecule.

An ethynyl radical is produced in Titan’s atmosphere by the photodissociation of acetylene by ultraviolet light.

Photodissociation is a process in which a chemical compound is broken down by photons.

“Surprisingly, the photochemical models show inconsistent mechanisms for the production of polyynes,” said Kaiser, who is the principal investigator of this study.

The mechanism involved in the formation of triacetylene, was also confirmed by accompanying theoretical calculations by Alexander Mebel, a theoretical chemist at Florida International University.

These theoretical computations also provide the 3D distribution of electrons in atoms and thus the overall energy level of a molecule.

To apply these findings to the real atmosphere of Titan, Danie Liang and Yuk Yung, planetary scientists at Taiwan’s Academia Sinica and California Institute of Technology (Caltech), respectively, performed photochemical modeling studies of Titan’s atmosphere.

All data together suggest that triacetylene may serve as a building block to form more complex and longer polyynes and produce potential precursors for the aerosol-based layers of haze surrounding Titan.

The study demonstrated for the first time that a sensible combination of laboratory simulation experiments with theory and modeling studies can shed light on decade old unsolved problems crucial to understand the origin and chemical evolution of the solar system.

The researchers hope to unravel next the mystery of the missing ethane lakes on Titan – postulated to exist for half a century, but not detected conclusively within the framework of the Cassini-Huygens mission.

In the future, the UH Manoa team will combine the research results with terrestrial-based observations of Titan’s atmosphere. (ANI)

Waste from TV screens may be recycled for medical purposes, say researchers

Washington, July 14 (ANI): University of York scientists say that it is possible to recycle waste material from discarded televisions to make them useful for medical purposes.

The researchers say that they have found a way to recover the chemical compound polyvinyl-alcohol (PVA) from television screens, and transform it into a substance which could be suitable for use in tissue scaffolds which help parts of the body regenerate.

They reckon that it could also be used in pills and dressings that are designed to deliver drugs to particular parts of the body.

Professor James Clark, director of the York Green Chemistry Centre of Excellence and one of the author’s of the research, said: “With 2.5 billion liquid crystal displays already reaching the end of their life, and LCD televisions proving hugely popular with consumers, that is a huge amount of potential waste to manage.”

He added: “It is important that we find ways of recycling as many elements of LCDs as possible so we don’t simply have to resort to burying and burning them.”

Describing their technique in an article published the journal Green Chemistry, the researchers have revealed that they heat recovered material in water in a microwave, and then wash it in ethanol to produce “expanded PVA”.

Given that this material does not provoke a response from the human immune system, the researchers say that it may be suitable for use in biomedicine. (ANI)

Chemical found in medical devices may impair heart function

Washington, May 1 (ANI): A chemical commonly used in the production of such medical plastic devices as intravenous (IV) bags and catheters can impair heart function in rats, researchers at the Johns Hopkins University School of Medicine have found.

Appearing online this week in the American Journal of Physiology, the new findings suggest a possible new reason for some of the common side effects-loss of taste, short term memory loss-of medical procedures that require blood to be circulated through plastic tubing outside the body, such as heart bypass surgery or kidney dialysis.

In addition to loss of taste and memory, coronary bypass patients often complain of swelling and fatigue. These side effects usually resolve within a few months after surgery, but they are troubling and sometimes hinder recovery.

His personal experience with coronary bypass surgery propelled his search for a root cause for the loss of taste phenomenon, reports principal investigator Artin Shoukas, Ph.D., professor of biomedical engineering, physiology and anesthesiology and critical care medicine at Johns Hopkins.

“I’m a chocoholic, and after my bypass surgery everything tasted awful, and chocolate tasted like charcoal for months,” Shoukas said.

The expert and Caitlin Thompson-Torgerson, Ph.D., a postdoctoral fellow in anesthesiology and critical care medicine suspected that the trigger for these side effects might be a chemical compound of some kind.

To test their theory, Shoukas and his team of researchers took liquid samples from IV bags and bypass machines before they were used on patients. The team analyzed the fluids in another machine that can identify unknown chemicals and found the liquid to contain a chemical compound called cyclohexanone.

The researchers thought that the cyclohexanone in the fluid samples might have leached from the plastic. Although the amount of cyclohexanone leaching from these devices varied greatly, all fluid samples contained at least some detectable level of the chemical.

The researchers then injected rats with either a salt solution or a salt solution containing cyclohexanone and measured heart function. Rats that got only salt solution pumped approximately 200 microliters of blood per heartbeat and had an average heart rate of 358 beats per minute, while rats injected with cyclohexanone pumped only about 150 microliters of blood per heartbeat with an average heart rate of 287 beats per minute.

In addition to pumping less blood more slowly, rats injected with cyclohexanone had weaker heart contractions. The team calculated that cyclohexanone caused a 50 percent reduction in the strength of each heart contraction. They also found that the reflex that helps control and maintain blood pressure is much less sensitive after cyclohexanone exposure. Finally, the team observed increased fluid retention and swelling in the rats after cyclohexanone injections.

According to Thompson-Torgerson and Shoukas, they would like to figure out how these side effects-decreased heart function and swelling-occur and to what degree cyclohexanone is involved. Despite the findings in this study, they emphasize that patients should listen carefully to the advice of their physicians.

“We would never recommend that patients decline this type of treatment if they need it,” says Shoukas. (ANI)